13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

257 trials found

diseases per page:

Showing 1 to 10 of 257 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05758831 (ClinicalTrials.gov)	February 28, 2023	17/2/2023	RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.	A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumabin Relapsing ...	Multiple Sclerosis;Relapsing-remitting Multiple Sclerosis	Drug: Perfusion of treatment Rituximab;Drug: Perfusion of treatment Ocrelizumab	Rennes University Hospital	NULL	Not yet recruiting	18 Years	55 Years	All	386	Phase 3	France
2	NCT05208840 (ClinicalTrials.gov)	February 14, 2023	12/1/2022	A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis	Open-Label Multicenter Study To Determine The Effect Of OcrelizumabOn Leptomeningeal Inflammation In ...	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	65 Years	All	50	Phase 4	Russian Federation
3	NCT05285891 (ClinicalTrials.gov)	January 12, 2023	8/3/2022	Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Randomized, Blinded Discontinuation Trial of Ocrelizumabin Early Relapsing Multiple Sclerosis (AMS05 ...	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Placebo for Ocrelizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence (ACE);Rho Federal Systems Division, Inc.;Genentech, Inc.	Recruiting	18 Years	55 Years	All	175	Phase 4	United States
4	EUCTR2021-005746-15-CZ (EUCTR)	14/09/2022	23/02/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of OcrelizumabIn Patients with Multip ...	A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety An ...	Primary Progressive Multiple Sclerosis (PPMS)Relapsing Multiple Sclerosis (RMS) MedDRA version: 21.1 ...	Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 INN or Proposed INN ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1300	Phase 3	United States;Serbia;Portugal;Belarus;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...
5	EUCTR2021-005746-15-FI (EUCTR)	06/07/2022	04/04/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of OcrelizumabIn Patients with Multip ...	A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety An ...	Primary Progressive Multiple Sclerosis (PPMS)Relapsing Multiple Sclerosis (RMS) MedDRA version: 21.1 ...	Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 INN or Proposed INN ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1300	Phase 3	Portugal;Serbia;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...
6	EUCTR2021-005746-15-NL (EUCTR)	04/07/2022	16/05/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of OcrelizumabIn Patients with Multip ...	A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety An ...	Primary Progressive Multiple Sclerosis (PPMS)Relapsing Multiple Sclerosis (RMS) MedDRA version: 21.1 ...	Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 INN or Proposed INN ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1300	Phase 3	Serbia;Portugal;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...
7	EUCTR2021-003296-33-GR (EUCTR)	17/06/2022	28/12/2021	OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMABON LEPTOMENINGEAL INFLAMMATION IN ...	OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMABON LEPTOMENINGEAL INFLAMMATION IN ...	Active progressive multiple sclerosis MedDRA version: 20.0;Level: HLT;Classification code 10052785;T ...	Trade Name: OCREVUS Product Name: OCRELIZUMAB Product Code: RO4964913 INN or Proposed INN: Ocrelizumab O ...	F. Hoffmann-La Roche Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 4	Greece;Russian Federation
8	EUCTR2020-004128-41-PT (EUCTR)	20/05/2022	21/09/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumabin Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Austr ...
9	EUCTR2021-005746-15-ES (EUCTR)	09/05/2022	10/05/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of OcrelizumabIn Patients with Multip ...	A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety An ...	Primary Progressive Multiple Sclerosis (PPMS)Relapsing Multiple Sclerosis (RMS) MedDRA version: 21.1 ...	Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 INN or Proposed INN ...	Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La R ...	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1300	Phase 3	Serbia;Portugal;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...
10	NCT05232825 (ClinicalTrials.gov)	May 3, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investiga ...	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical ...	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: Dex ...	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	65 Years	All	234	Phase 3	United States;Australia;Brazil;Czechia;Italy;New Zealand;Poland;Spain;Turkey;Canada;Russian Federati ...

First Previous1 2 3 4 5…26Next Last